In parallel with NAFLD, there was also a marked increase in hepatic CYP2E1 activity in obese T2DM patients, one of the most common risk factors for NAFLD, as assessed by chlorzoxazone administration [60]. The gene discussed is CYP2E1; the disease is metabolic dysfunction-associated steatotic liver disease.